1	TO THE HOUSE OF REPRESENTATIVES:
2	The Committee on Health Care to which was referred House Bill No. 309
3	entitled "An act relating to substitution of epinephrine autoinjector devices"
4	respectfully reports that it has considered the same and recommends that the
5	bill be amended by striking out all after the enacting clause and inserting in
6	lieu thereof the following:
7	Sec. 1. 18 V.S.A. § 4605 is amended to read:
8	§ 4605. ALTERNATIVE DRUG SELECTION
9	* * *
10	(e)(1) If a purchaser is prescribed an epinephrine autoinjector device and
11	there is an alternate epinephrine autoinjector product available that would
12	reflect a lower cost to the purchaser, the pharmacist shall, regardless of
13	whether the alternate epinephrine autoinjector product is included in the latest
14	list of interchangeable drug products for the prescribed epinephrine
15	autoinjector device, do all of the following:
16	(A) advise the purchaser of the availability of the alternate
17	epinephrine autoinjector product;
18	(B) advise the purchaser of the potential cost difference between the
19	prescribed device and the alternate product;
20	(C) advise the purchaser of any difference in administration
21	between the prescribed device and the alternate product;

1	(D) provide training or other instruction to the purchaser on the
2	use of the alternate product; and
3	(E) with the purchaser's consent, dispense the alternate epinephrine
4	autoinjector product to the purchaser.
5	(2) Notwithstanding the provisions of subdivision (1) of this subsection,
6	if the prescriber has indicated that substitution is not permissible, the
7	pharmacist shall dispense the epinephrine autoinjector device as prescribed.
8	Sec. 2. EFFECTIVE DATE
9	This act shall take effect on July 1, 2017.
10	
11	
12	
13	
14	
15	
16	
17	(Committee vote:)
18	
19	Representative
20	FOR THE COMMITTEE